• There are no items in your cart

ISO 13022:2012

Current
Current

The latest, up-to-date edition.

Medical products containing viable human cells — Application of risk management and requirements for processing practices
Available format(s)

Hardcopy , PDF , PDF 3 Users , PDF 5 Users , PDF 9 Users

Language(s)

English, Russian

Published date

03-21-2012

This International Standard specifies requirements and guidance for processing practices and managing risk

associated with viable cellular components of products regulated as medicinal products, biologics, medical

devices and active implantable medical devices, or combinations thereof. It covers viable human materials of

autologous as well as allogeneic human origin, obtained from living or deceased donors.

For manufacturers of medical products containing viable cells of human origin, this International Standard

specifies procedures to be used in processing and handling, as well as those to be used in identifying the

hazards and hazardous situations associated with such cells, in order to estimate and evaluate the resulting

risks, to control these risks, and to monitor the effectiveness of that control. Furthermore, this International

Standard outlines the decision process for the residual risk acceptability, taking into account the balance of

residual risk and expected medical benefit as compared to available alternatives.

This International Standard provides requirements and guidance on risk management related to the hazards

typical of medical products manufactured utilizing viable human materials, such as:

a) contamination by bacteria, moulds, yeasts or parasites;

b) contamination by viruses;

c) contamination by agents causing Transmissible Spongiform Encephalopathies (TSE);

d) contaminating material responsible for undesired pyrogenic, immunological or toxicological reactions;

e) decomposition of the product and degradation products caused by inadequate handling;

f) hazards related to the tumorigenic potential of the cell types used;

g) complications resulting from unintended physiological and anatomical consequences (this includes

unintended migration of cells, unwanted release of biologically active substances such as hormones and

cytokines, and unintended interactions between cellular and non‑cellular components of the product);

h) failure of traceability;

i) complications resulting from the material eliciting an unintended immunogenic reaction.

For the evaluation of contamination with other unclassified pathogenic entities, similar principles might be applicable.

Hazards related to genetic modification are outside the scope of this International Standard and are

addressed elsewhere.

NOTE 1 A definition of "genetically modified" can be found in ASTM F2312.

NOTE 2 This International Standard does not specify a quality management system for the control of all stages of

production of medical products as described above.

If additional national or regional criteria beyond what is defined in this International Standard exist in the

country where the medical product will be used, they are also applicable.

NOTE 3 Regional requirements can be more stringent than requirements referenced in this International Standard,

especially with regard to donor eligibility criteria.

This International Standard is not applicable to:

— non‑viable materials of human origin;

— viable cells of non‑human origin;

— blood and its components used for transfusion, germ cells, organs and bone marrow used for transplantation,

and other tissues that do not meet the definition of "medical product";

in vitro diagnostic devices.

NOTE 4 For guidance on the application of this International Standard, see Annex A.

DevelopmentNote
Supersedes ISO/DIS 13022. (03/2012)
DocumentType
Standard
Pages
48
ProductNote
THIS STANDARD ALSO REFERS TO CWA 15849
PublisherName
International Organization for Standardization
Status
Current

Standards Relationship
NEN ISO 13022 : 2012 Identical
DIN ISO 13022 E : 2014 Identical
GOST R ISO 13022 : 2016 Identical
DIN ISO 13022:2014-06 Identical
ANSI/AAMI/ISO 13022:2012 Identical

I.S. EN ISO 11737-1:2018&LC:2018 STERILIZATION OF HEALTH CARE PRODUCTS - MICROBIOLOGICAL METHODS - PART 1: DETERMINATION OF A POPULATION OF MICROORGANISMS ON PRODUCTS (ISO 11737-1:2018)
ISO 11737-1:2018 Sterilization of health care products — Microbiological methods — Part 1: Determination of a population of microorganisms on products
14/30266295 DC : 0 BS ISO 18362 - PROCESSING OF CELL-BASED HEALTH CARE PRODUCTS
ISO 13019:2018 Tissue-engineered medical products — Quantification of sulfated glycosaminoglycans (sGAG) for evaluation of chondrogenesis
17/30319534 DC : 0 BS ISO 13019 - TISSUE-ENGINEERED MEDICAL PRODUCTS - QUANTIFICATION OF SULPHATED GLYCOSAMINOGLYCANS (SGAG) FOR EVALUATION OF CHONDROGENESIS
ISO 18362:2016 Manufacture of cell-based health care products Control of microbial risks during processing
ASTM F 3223 : 2017 Standard Guide for Characterization and Assessment of Tissue Engineered Medical Products (TEMPs) for Knee Meniscus Surgical Repair and/or Reconstruction
BS ISO 18362:2016 Manufacture of cell-based health care products. Control of microbial risks during processing

ISO 13408-4:2005 Aseptic processing of health care products — Part 4: Clean-in-place technologies
ISO/TR 22442-4:2010 Medical devices utilizing animal tissues and their derivatives Part 4: Principles for elimination and/or inactivation of transmissible spongiform encephalopathy (TSE) agents and validation assays for those processes
ASTM F 2386 : 2004 Standard Guide for Preservation of Tissue Engineered Medical Products (TEMPs) (Withdrawn 2013)
ISO 7010:2011 Graphical symbols Safety colours and safety signs Registered safety signs
ASTM F 2312 : 2011 : REDLINE Standard Terminology Relating to Tissue Engineered Medical Products
ASTM F 2149 : 2016 : REDLINE Standard Test Method for Automated Analyses of Cells—the Electrical Sensing Zone Method of Enumerating and Sizing Single Cell Suspensions
BS PAS 84(2008) : 2008 REGENERATIVE MEDICINE - GLOSSARY
ISO 13408-2:2003 Aseptic processing of health care products Part 2: Filtration
ISO 13485:2016 Medical devices Quality management systems Requirements for regulatory purposes
CFR 21(PTS800-1299) : 0 FOOD AND DRUGS - FOOD AND DRUG ADMINISTRATION, CHAPTER 1 DEPARTMENT OF HEALTH AND HUMAN SERVICES - PARTS 800-1299
ASTM F 2385 : 2015 : REDLINE Standard Practice for Determining Femoral Head Penetration into Acetabular Components of Total Hip Replacement Using Clinical Radiographs
ISO 22442-1:2015 Medical devices utilizing animal tissues and their derivatives Part 1: Application of risk management
ASTM F 2383 : 2011 : REDLINE Standard Guide for Assessment of Adventitious Agents in Tissue Engineered Medical Products (TEMPs)
ASTM F 2027 : 2016 : REDLINE Standard Guide for Characterization and Testing of Raw or Starting Materials for Tissue-Engineered Medical Products
ISO 13408-3:2006 Aseptic processing of health care products Part 3: Lyophilization
ISO/IEC Guide 51:2014 Safety aspects Guidelines for their inclusion in standards
EN 166:2001 Personal eye-protection - Specifications
ISO 13408-1:2008 Aseptic processing of health care products — Part 1: General requirements
ASTM F 2739 : 2016 Standard Guide for Quantifying Cell Viability within Biomaterial Scaffolds
ISO 22442-2:2015 Medical devices utilizing animal tissues and their derivatives Part 2: Controls on sourcing, collection and handling
EN 511:2006 Protective gloves against cold
ASTM F 2211 : 2013 Standard Classification for Tissue Engineered Medical Products (TEMPs)
ISO 14155:2011 Clinical investigation of medical devices for human subjects Good clinical practice
ISO 22442-3:2007 Medical devices utilizing animal tissues and their derivatives — Part 3: Validation of the elimination and/or inactivation of viruses and transmissible spongiform encephalopathy (TSE) agents
ISO 14971:2007 Medical devices Application of risk management to medical devices
EN 1251-3:2000 Cryogenic vessels - Transportable vacuum insulated vessels of not more than 1000 litres volume - Part 3: Operational requirements
ISO 13408-6:2005 Aseptic processing of health care products Part 6: Isolator systems
EN 13458-3:2003/A1:2005 CRYOGENIC VESSELS - STATIC VACUUM INSULATED VESSELS - PART 3: OPERATIONAL REQUIREMENTS
ISO 13408-5:2006 Aseptic processing of health care products Part 5: Sterilization in place

View more information
US$201.00
Excluding Tax where applicable

Access your standards online with a subscription

Features

  • Simple online access to standards, technical information and regulations.

  • Critical updates of standards and customisable alerts and notifications.

  • Multi-user online standards collection: secure, flexible and cost effective.